Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Lung Neoplasms 76Leukemia, Myeloid, Acute 71Prostatic Neoplasms 67Neoplasm Metastasis 56Carcinoma, Non-Small-Cell Lung 56Breast Neoplasms 45Multiple Myeloma 44Colorectal Neoplasms 41Pancreatic Neoplasms 37Myelodysplastic Syndromes 35Carcinoma, Renal Cell 33Ovarian Neoplasms 31Melanoma 30Leukemia, Lymphocytic, Chronic, B-Cell 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Glioblastoma 27Triple Negative Breast Neoplasms 26Lymphoma, Large B-Cell, Diffuse 26Urinary Bladder Neoplasms 24Lymphoma 23Burkitt Lymphoma 22Squamous Cell Carcinoma of Head and Neck 21Glioma 20Fallopian Tube Neoplasms 20Carcinoma, Hepatocellular 18Mouth Neoplasms 17Leukemia, Biphenotypic, Acute 17Brain Neoplasms 17Sarcoma 16Oropharyngeal Neoplasms 16

Interventions

Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2pembrolizumab 1enfortumab vedotin 1cabozantinib 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Urachal adenocarcinoma × Specimen Handling × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT05756569 2025-07-28

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Emory University

Phase 2 Recruiting
25 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡